submarine illuminating bottom of ocean with red light

Going deep with NIR-II light

Learn more about this and other topics in our June issue

  • Zeyu Zhang
  • Yang Du
  • Jie Tian
Review Article

Announcements

  • charts overlaid with maps

    In this Collection, you can find the latest articles published in Nature Reviews Clinical Oncology that discuss trends in cancer incidence and mortality.

  • viral particles floating

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic.

Advertisement

    • Artificial intelligence (AI) has the potential to dramatically change several aspects of oncology including diagnosis, early detection and treatment-related decision making. However, many of the underlying algorithms have been or are being trained on datasets that do not necessarily reflect the diversity of the target population. For this, and other reasons, many AI tools might not be suitable for application in less economically developed countries and/or in patients of certain ethnicities. In this Perspective, the authors discuss possible sources of inequity in AI development, and how to ensure the development and implementation of equitable AI tools for use in patients with cancer.

      • Vidya Sankar Viswanathan
      • Vani Parmar
      • Anant Madabhushi
      Perspective
    • Increasing evidence indicates that intratumoural bacteria can have crucial roles in both the pathogenesis and treatment of cancer. In this Review, the authors discuss the characteristics of intratumoural bacteria and the emerging understanding of their tumour-promoting and antitumour activities. They also describe a range of innovative strategies that are being used to engineer bacteria for use in the treatment of cancer and summarize clinical trials of various bacteria-mediated cancer immunotherapies.

      • Seong-Young Kwon
      • Hien Thi-Thu Ngo
      • Jung-Joon Min
      Review Article
    • Following the introduction of blinatumomab in 2014, the past 4 years have seen the approval of a further ten bispecific antibodies, reflecting substantial research effort and clinical interest in these agents. In this Review, the authors describe the developments leading to the approval of these novel agents and highlight important future research directions, including clinical optimization as well as innovative antibody engineering approaches.

      • Maria-Elisabeth Goebeler
      • Gernot Stuhler
      • Ralf Bargou
      Review Article
    • De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.

      • Maria Vittoria Dieci
      • Valentina Guarneri
      News & Views
    • The majority of patients with cancers of unknown primary have unfavourable outcomes when they receive empirical chemotherapy. The shift towards using precision medicine-based treatment strategies involves two options: tissue-agnostic or site-specific approaches. Here, we reflect on how cytology-based deep learning tools can be leveraged in these approaches.

      • Elie Rassy
      • Nicholas Pavlidis
      News & Views

Nature Careers

Science jobs

Advertisement